Clinical trial
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With…
NCT00068757 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00068757 |
|---|---|
| Title | Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer |
| Official title | Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, lonafarnib, paclitaxel, pharmacological study |
| Enrollment | 23 |
| Start date | Aug 1, 2003 |
| Primary completion | Nov 1, 2007 |
| First posted | Sep 11, 2003 |
| Last update posted | Sep 12, 2012 |
| Countries | Belgium, France, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: